
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short ...
Treatment with the combination of relacorilant and nab-paclitaxel (Abraxane) was associated with survival benefits vs nab-paclitaxel alone in poor-prognosis subgroups of patients with platinum-resistant ovarian cancer, including those with a primary …